1 Jun 2021 7:39 am
To date, the efficacy of ivermectin in COVID-19 has been supported by the following:
- Since 2012, multiple in vitro studies have demonstrated that Ivermectin inhibits the replication of many viruses, including influenza, Zika, Dengue, and others.9–17
- Ivermectin inhibits SARS-CoV-2 replication and binding to host tissue through several observed and proposed mechanisms.18
- Ivermectin has potent anti-inflammatory properties with in vitro data demonstrating profound inhibition of both cytokine production and transcription of nuclear factor-κB (NF-κB), the most potent mediator of inflammation.37–39
- Ivermectin significantly diminishes viral load and protects against organ damage in multiple animal models when infected with SARS-CoV-2 or similar coronaviruses.31,32
- Ivermectin prevents transmission and development of COVID-19 disease in those exposed to infected patients.40–45
- Ivermectin hastens recovery and prevents deterioration in patients with mild to moderate disease treated early after symptoms.45,49–52,61,62
- Ivermectin hastens recovery and avoidance of ICU admission and death in hospitalized patients.45,51,53,63–66
- Ivermectin reduces mortality in critically ill patients with COVID-19.45,53,63
- Ivermectin leads to temporally associated reductions in case fatality rates in regions after ivermectin distribution campaigns.48
- The safety, availability, and cost of ivermectin are nearly unparalleled given its low incidence of important drug interactions along with only mild and rare side effects observed in almost 40 years of use and billions of doses administered.75
- The World Health Organization has long included ivermectin on its “List of Essential Medicines.”
...